FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers
Roche is getting some help from the FDA in its quest to start making up some of the multibillion-dollar distance that separates the global player from Merck and Bristol-Myers Squibb in the blockbuster rivalry over the lung cancer market. The agency is handing Roche and its big cancer division Genentech a priority review for a triple using its PD-L1 checkpoint Tecentriq plus Avastin and chemo in frontline lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.